Replimune
HCP (unbranded)
Replimune is working on the “next generation” of cancer treatments, focusing on the use of oncolytic viruses to initiate immune response and lyse cancer cells. We worked on the unbranded campaign leading up to the launch of RP1, their innovative tumor-directed oncolytic immunotherapy (TDOI) for advanced skin cancers.
Client: Replimune
Year: 2023
Brief: Unbranded brochure focusing on DSE, need for more effective and tolerable therapies, and promise of TDOI as a new treatment
Creative Directors: Danielle Wozniak, Jess Lam
Copywriters: Kelly Slonaker, Kayla Velazquez
Art Directors: Yunuén Sigler
Work done at FCBHealthNY (RIP 🥲)
